Circulating Levels of Inflammatory Markers and Cancer Risk in the Health Aging and Body Composition Cohort

Il’yasova, Dora; Colbert, Lisa H.; Harris, Tamara B.; Newman, Anne B.; Bauer, Douglas C.; Satterfield, Suzanne; Kritchevsky, Stephen B.

doi:10.1158/1055-9965.epi-05-0316

Cited by 411 publications

(386 citation statements)

References 43 publications

Supporting

Mentioning

349

Contrasting

Unclassified

Order By: Relevance

“…Studies have demonstrated that the levels of proinflammatory cytokines were increased in systemic circulation of patients diagnosed with prostate cancer [21][22][23]. We have previously demonstrated the The Prostate DOI 10.1002/pros Fig.…”

Section: Discussionmentioning

confidence: 90%

Molecular imaging of NF‐kappaB in prostate tissue after systemic administration of IL‐1β

et al. 2007

View full text Add to dashboard Cite

BACKGROUND. Activation of nuclear-factor kappaB (NF-kB) influences the transcription of number of genes, many of which participate in inflammatory responses and tumor development. A wide range of human cancers and inflammatory disorders express inappropriate regulation of NF-kB. The role of NF-kB in intraprostatic inflammation has not been elucidated. METHODS. Using transgenic NF-kB-Luciferase Tag mice coupled to the luciferase reporter gene, we performed serial, noninvasive in vivo and ex vivo molecular imaging of NF-kB activation in the mouse body after systemic administration of mouse pro-inflammatory cytokines: TNF-a, IL-6, and IL-1b at 10 mg/kg body weights. In some experiments, pretreatment with dexamethasone (10 mg/kg) was used to modulate the cytokine-induced NF-kB-dependent luminescence in vivo. RESULTS. Treatment of NF-kB-Luc mice with cytokines increased luminescence in a time-and organ-specific manner. Highest levels of NF-kB-dependent luminescence were observed approximately 3-4 hr after IL-1b administration. An important finding was the cumulative effect of IL-1b to activate NF-kB in the prostate during chronic administration. CONCLUSIONS. The molecular imaging of NF-kB activity might be an attractive approach to distinguish the role of cytokine-induced NF-kB signaling in intraprostatic inflammation and prostate cancer development. Since dexamethasone, a known NF-kB inhibitor, could reduce the IL-1b-induced NF-kB-dependent luminescence in the prostate, NF-kB-Luc mice might be useful tool to screen potential candidate drugs for treatment of inflammation and tumor associated with aberrant NF-kB activity.

show abstract

Section: Discussionmentioning

confidence: 90%

Molecular imaging of NF‐kappaB in prostate tissue after systemic administration of IL‐1β

et al. 2007

View full text Add to dashboard Cite

show abstract

“…For reporting different cancer type, both studies of Zhang et al (2007) and Zhang et al (2005) were inclusive, although their participants were from the same population. At last, 10 articles (Il'Yasova et al, 2005;Zhang et al, 2005;Siemes et al, 2006;Zhang et al, 2007;Allin et al, 2009;Heikkila et al, 2009;Pierce et al, 2009;Dos et al, 2010;Prizment et al, 2011;Van et al, 2011) including 11 cohort studies were eligible for inclusion criteria in this meta-analysis (one article including two separate cohorts (Heikkila et al, 2009)), involving a total of 194,796 participants and 11,459 cancer cases. Table 1 summarizes the baseline characteristics of 11 cohort studies included.…”

Section: Resultsmentioning

confidence: 99%

“…In studies of Van et al (2011) and Siemes et al (2006) where HR was reported based on various length of followup, the HR with the longer follow-up was used to compute. The results of a pooled analysis in all 11 included cohort studies (Il'Yasova et al, 2005;Zhang et al, 2005;Siemes et al, 2006;Zhang et al, 2007;Allin et al, 2009;Heikkila et al, 2009;Pierce et al, 2009;Dos et al, 2010;Prizment et al, 2011;Van et al, 2011) are shown in Figure 2. The overall pooled HR per natural log unit change in CRP for all-cancer was 1.105 (95% CI: 1.033-1.178), with substantial heterogeneity amongst studies (P heterogeneity =0.000, I 2 =70.10%).…”

Section: Resultsmentioning

confidence: 99%

“…Among them, most case-control studies have shown a higher cancer risk in people with elevated CRP levels (Gunter et al, 2006;Helzlsouer et al, 2006;Otani et al, 2006;Aleksandrova et al, 2010;Chaturvedi et al, 2010;Lee et al, 2011;Pine et al, 2011), while, the findings from prospective cohort studies have been inconsistent (Il'Yasova et al, 2005;Zhang et al, 2005;Siemes et al, 2006;Zhang et al, 2007;Allin et al, 2009;Heikkila et al, 2009;Pierce et al, 2009;Dos et al, 2010;Prizment et al, 2011;Van et al, 2011).…”

Section: Association Between C-reactive Protein and Risk Of Cancer: Amentioning

confidence: 99%

See 1 more Smart Citation

Association Between C-reactive Protein and Risk of Cancer: A Meta-analysis of Prospective Cohort Studies

Guo

Pan²,

Du³

et al. 2013

Asian Pacific Journal of Cancer Prevention

130

View full text Add to dashboard Cite

“…Several small case-control studies have suggested serum IL-6 is increased in women with breast cancer [14]. Recently, Il'yasova et al [15] reported increased serum CRP was associated with incident breast cancer in a cohort of post-menopausal women. Polymorphisms in the IL6 gene promoter, −572G/C and the -174G/C, have been reported to be related to levels of circulating CRP [16] and to breast cancer [17].…”

Section: Introductionmentioning

confidence: 99%

Active and passive smoking, IL6, ESR1, and breast cancer risk

Slattery

Curtin

Giuliano

et al. 2007

Breast Cancer Res Treat

View full text Add to dashboard Cite

We evaluated the association between smoking and risk of breast cancer in non-Hispanic white (NHW) and Hispanic or American Indian (HAI) women living in the Southwestern United States. Data on lifetime exposure to active and passive smoke data were available from 1527 NHW cases and 1601 NHW controls; 798 HAI cases and 924 HAI controls. Interleukin 6 (IL6) and Estrogen Receptor alpha (ESR1) polymorphisms were assessed in conjunction with smoking. Pack-years of smoking (≥15) were associated with increased risk of pre-menopausal breast cancer among NHW women (OR 1.6, 95% CI 1.1-2. 4). Passive smoke increased risk of pre-menopausal breast cancer for HAI women (OR 1.9, 95% CI 1.1-3.1 everyone; OR 2.3, 95% CI 1.2-4.5 nonsmokers). HAI premenopausal women who were exposed to 10+ h of passive smoke per week and had the rs2069832 IL6 GG genotype had over a fourfold increased risk of breast cancer (OR 4.4, 95% CI 1.5-12.8; P for interaction 0.01). Those with the ESR1 Xba1 AA genotype had a threefold increased risk of breast cancer if they smoked ≥15 pack-years relative to non-smokers (P interaction 0.01). These data suggest that breast cancer risk is associated with active and passive smoking.

show abstract

Circulating Levels of Inflammatory Markers and Cancer Risk in the Health Aging and Body Composition Cohort

Cited by 411 publications

References 43 publications

Molecular imaging of NF‐kappaB in prostate tissue after systemic administration of IL‐1β

Molecular imaging of NF‐kappaB in prostate tissue after systemic administration of IL‐1β

Association Between C-reactive Protein and Risk of Cancer: A Meta-analysis of Prospective Cohort Studies

Active and passive smoking, IL6, ESR1, and breast cancer risk

Contact Info

Product

Resources

About